Abstract Body

Background: In one of the largest randomized, double-blind, placebo-controlled phase 2 therapeutic HIV vaccine clinical trials, Vacc-4x was found safe, well-tolerated and immunogenic. While on combination antiretroviral therapy (cART), 135 HIV-infected participants (vaccine: placebo = 92: 43) were randomized and received 4 weekly immunizations followed by booster immunizations at weeks 16 and 18. At week 28, cART was interrupted for up to 24 weeks. Based on the primary analyses, Vacc-4x did not significantly reduce the proportion of participants resuming cART or change in CD4 counts during the cART interruption. We assessed the vaccine effect based on additional exploratory endpoints.

Methods: All analyses included per-protocol (PP) participants who received the full immunization and underwent cART interruption. Linear regression models were used to identify predictors of outcomes measured after cART interruption, and to estimate the vaccine effect adjusted for potential baseline confounding factors. We assessed vaccine effect based on four novel preART-adjusted clinical endpoints: fold changes in CD4 counts at week 40 or in the geometric mean of CD4 counts at weeks 48 and 52 over preART CD4 counts, and fold changes in viral load (VL) at week 40 or in the geometric mean of VL at weeks 48 and 52 over preART VL. We used a multiple imputation approach to account for missing CD4 counts or VL due to cART resumption or dropout.

Results: PreART CD4 counts and VL were significant predictors of levels after cART interruption. A significant vaccine effect was observed in the analysis of all four preART-adjusted endpoints. Compared to the placebo recipients, the vaccine recipients had a higher fold change in week 40 CD4 counts (vaccine vs. placebo mean fold-change difference = 0.08; 95% CI 0.02, 0.15; p=0.02), a higher fold change in weeks 48/52 CD4 counts (0.07; 95% CI 0.01, 0.13; p=0.03), a lower fold change in week 40 VL (-0.46; 95% CI -0.88 to -0.04; p=0.03), and a lower fold change in weeks 48/52 VL (-0.44; 95% CI -0.86, -0.02; p=0.04).

Conclusions: These exploratory analyses consistently suggested that Vacc-4x provided improved effect on preART-adjusted clinical endpoints for CD4 counts and VL over participants’ preART conditions. Future HIV therapeutic vaccine studies may adopt similar endpoints of fold changes over preART values to account for participants’ heterogeneity and to increase the statistical power of vaccine effect evaluations.